A Phase 1b Study of BCL-XL Degrader DT2216 in Combination With Weekly Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
The clinical trial for DT2216, a BCL-XL degrader, in combination with paclitaxel, targets recurrent platinum-resistant ovarian cancer, a significant unmet medical need in oncology. The study aims to establish the maximum tolerated dose (MTD) and evaluate safety, which could position DT2216 as a novel therapeutic option in a competitive landscape dominated by established chemotherapies. Given the FDA's approval of paclitaxel, the combination therapy may enhance treatment efficacy and patient outcomes. The involvement of the Department of Defense and Dialectic Therapeutics indicates potential for strategic partnerships and funding opportunities. Market entry could disrupt existing treatment paradigms if safety and efficacy are demonstrated, leading to significant commercial potential in a market projected to grow as new therapies are sought for resistant cancer types.
Indication: Ovarian Cancer
Modality: small molecule
Target: BCL-XL protein (degradation via proteolysis-targeting chimera mechanism)
Sponsor: Elizabeth Stover, MD, PhD
Source URL: ClinicalTrials.gov
Source updated: Apr 21, 2026
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: BCL-XL protein (degradation via proteolysis-targeting chimera mechanism)
View original source fields
Condition raw: Ovarian Cancer, Ovarian Carcinoma, Recurrent Ovary Cancer, Recurrent Platinum-Resistant Ovarian Carcinoma
Condition normalized: Ovarian Cancer, Ovarian Carcinoma, Recurrent Ovary Cancer, Recurrent Platinum-Resistant Ovarian Carcinoma
Modality raw: small molecule
Modality normalized: small molecule
Target raw: BCL-XL protein (degradation via proteolysis-targeting chimera mechanism)
Target normalized: BCL-XL protein (degradation via proteolysis-targeting chimera mechanism)